Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Jun 30, 2025	Dec 31, 2024
Net Income	-107.59	-91.34
Depreciation & Amortization	0.06	0.03
Loss (Gain) From Sale of Investments	-5.75	-2.45
Stock-Based Compensation	25.47	16.28
Other Operating Activities	1.92	1.74
Change in Accounts Payable	-11.81	10.35
Change in Other Net Operating Assets	1.79	2.3
Operating Cash Flow	-95.91	-63.09
Capital Expenditures	-0.25	-0.21
Investment in Securities	-312.16	-359.93
Investing Cash Flow	-312.41	-360.14
Total Debt Issued	2.27	27.25
Net Debt Issued (Repaid)	2.27	27.25
Issuance of Common Stock	454.68	454.57
Other Financing Activities	6.98	5.39
Financing Cash Flow	464.19	490.41
Net Cash Flow	55.87	67.17
Free Cash Flow	-96.16	-63.3
Free Cash Flow Per Share	-2.66	-3.77
Change in Working Capital	-10.02	12.64

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q